Nutra Pharma Corp. (OTCMKTS:NPHC) Treatment of HIV, Arthritis, MS

Nutra Pharma Corp. (OTCMKTS:NPHC) Treatment of HIV, Arthritis, MS

Nutra Pharma Corp. (OTCMKTS:NPHC) Treatment of HIV, Arthritis, MS

Nutra Pharma, through its subsidiary ReceptoPharm, has a pipeline of biopharmaceutical products under development. These research and development pipeline products consist of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis, HIV/AIDS, adrenomyeloneuropathy, herpes, rheumatoid arthritis and pain.

Nutra Pharma Corp. (OTCMKTS:NPHC) holds a license to certain intellectual property from Bio Therapeutics, which it intends to utilize in conjunction with Receptopharm’s research and development of modified venom and peptides thereof in applications for the treatment of HIV and MS.

Patents

  • U.S. Patent No. 5,989,857, which was granted in November 1999 with 10 claims.
  • U.S. Patent No. 6,670,148, which was granted in December 2003, with 9 claims. The patent further describes the method for preparing a bioactive peptide (protein) found in cobra venom, in a stable, inactivated form, by treating the peptide with ozone.
  • Buccal Delivery System, on which a patent is pending. This application describes a throat spray that permits efficient delivery of the modified peptide drugs to the body through oral mucosa.
  • Technology contained in one pending U.S. patent application for the further development of bioactive peptides in cobra venom for use in the treatment of HIV and MS.
  • Technology contained in two pending U.S. patent applications for Immunokine Composition and Method, which describes a method for developing modified peptides from alpha-cobratoxin.
  • Technology contained in two patents pending for the topical delivery of our proprietary wound healing treatment, which was developed in conjunction with Bio Therapeutics. One of these products is in the form of an ointment style skin protectant and the other a foaming aerosol.

ReceptoPharm’s research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.

Planning
In Progress
Completed

Abbreviations
Preclinical (PC), Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)

RPI-78M

Indication
PC
P-I
P-II
P-III
Herpes Simplex Infections 1 & 2

RPI-MN

Indication
PC
P-I
P-II
P-III
Human Immunodeficiency Virus
Amyotrophic Lateral Sclerosis
Herpes Simplex Keratitis

RPI-78

Indication
PC
P-I
P-II
P-III

Cobroxin

Indication
Regulatory Status
Chronic Pain (OTC)
Marketing

 

Cobroxin for Chronic Pain
Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information, visit http://www.Cobroxin.com.

Nyloxin

Indication
Regulatory Status
Chronic Pain Marketing

 

Nyloxin // Chronic Pain Relief
Nyloxin is an over-the-counter (OTC) pain reliever for the treatmentment of moderate to severe chronic pain. It is available as both an oral spray and as a topical gel. Nyloxin is specifically formulated to treat back pain, neck pain, headaches, joint pain, migraines, arthritis pain, pain from repetitive stress and neuralgia. For more information, visit http://www.Nyloxin.com.
The following two tabs change content below.
Shayne Heffernan Funds Manager at HEFFX holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Mining, Shipping, Technology and Financial Services.

Latest posts by Shayne Heffernan (see all)

You must be logged in to post comments :  
CONNECT WITH